Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (February 2026)
28 slides from Revelation Biosciences's investor presentation, Feb 26, 2026
Slide 1: Corporate Presentation
Corporate Presentation NASDAQ: REVB January 2026 www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the w
Slide 3: Gemini Programs and Market Potential
Gemini Programs and Market Potential Intellectual Patient Market Program Therapeutic Indication Property Population Potential Next Milestone GEM-AKI Acute Kidney Injury Wholly-Owned 2.3 Million $5 Billion Phase 2/3 GEM-CKD Chronic Kidney Disease Wholly-Owned 37 Million $9 Billion Phase 2 Licensed fr
Slide 4: Programs
Programs 4
Slide 5: AKI Program Fast Facts
AKI Program Fast Facts The Problem: Acute kidney Injury (AKI) • Severe AKI (stage 3) • A sudden decrease in kidney function Driven by • Need for dialysis excessive inflammation • Longer recovery • ~50% of all ICU patients develop AKI (20% of all • Higher mortality (>50%) hospitalized)1 • Reduced AKI
Slide 6: Gemini Phase 2/3 Adaptive 2-Part Study
Gemini Phase 2/3 Adaptive 2-Part Study1 Part 1 (Phase 2): Severe stage 2 or stage 3 acute kidney injury patients not yet on dialysis will be administered Gemini or placebo. Multiple dosing regimens will be evaluated Adaptation: The Safest dosing regimen will be determined and graduated to Part 2 and
Slide 7: AKI Scientific Advisory Board
AKI Scientific Advisory Board Revelation has engaged the Renal & Cardiometabolic Center of Excellence (RCM CoE) • To solicit feedback from regional scientific experts around the study design • To ensure the protocol is optimized for both patients and investigators • To engage with key opinion leader
Slide 8: CKD Program Fast Facts
CKD Program Fast Facts The Problem: CKD is a chronic decrease in kidney function ultimately leading to dialysis • Driven by inflammation • ~10% of global population have CKD • Numerous risk factors including prior AKI, hypertension, obesity, diabetes The Solution: GEMINI • Gemini has been shown to c
Slide 9: Burn Program Fast Facts
Burn Program Fast Facts The Problem: Severe burn patients suffer from hyperinflammation and have increased risk of severe systemic inflammatory response syndrome and sepsis, and are at risk of immunosuppression The Solution: GEMINI • Corrects hyper inflammation while restoring immunocompetence • Exp
Slide 10: The Science
The Science 10
Slide 11: TLR4 stimulation via PHAD can rebalance cellular equilibrium, fostering healing processes
TLR4 stimulation via PHAD can rebalance cellular equilibrium, fostering healing processes Hyperinflammation Immunosuppression • Cellular infiltration • Cellular senescence • Sustained immune response, cytokines • Removal of inflammatory signals • Highly cytotoxic environment • Reduced cellular immun
Slide 12: Gemini is a Safer TLR4 Agonist
Gemini is a Safer TLR4 Agonist Immunomobilization - Cells sent to where they are needed Balanced immune response - lower pro- inflammatory cytokine production, intact anti- inflammatory cytokine production Durable reprogramming of cellular metabolism Restoration of immunocompetence - Observed out to
Slide 13: Multiple Inflammatory Diseases may benefit from Gemini
Multiple Inflammatory Diseases may benefit from Gemini Neurodegenerative Diseases • Parkinson's • Alzheimer's Disease Cardiovascular Disease • Myocarditis Hepatic Disease • Pericarditis • MASH • Cardiorenal Syndrome • IgA Nephropathy Renal Disease Inflammatory Bowel Disease • Acute Kidney Injury • C
Slide 14: Financial Overview
Financial Overview 14
Slide 15: Financial Overview
Financial Overview Key Financial Summary 9/30/2025 Beneficial Holders Shares % Cash $12,708,489 Management 843,373 13.31 Stockholders Equity $11,001,835 Total 843,373 13.31 Cash Used for Operations $6,302,589 Cash Provided by Financing $12,512,060 Cap Table Shares Common Stock 6,335,804 Common Stock
Slide 16: Experienced Management
Experienced Management Experienced management Successful track record in A history of building Management has broad and scientific team multiple startups and turn- successful commercial experience in financings and arounds including organizations investor relations Extensive product development expe
Slide 17: Key Takeaways
Key Takeaways • Agreement with FDA on clear path to approval for Gemini for treatment of AKI o Single adaptive Phase 2/3 study with clinically relevant and achievable primary composite endpoint • Enormous market potential • A well experienced management with a proven track record • We have shown Gem
Slide 18: Thank You!
Thank You! For more information, please visit www.revbiosciences.com 18
Slide 19: Supplemental Slides
Supplemental Slides BIOSCIENCES
Slide 20: AKI is a significant Problem: A deeper dive
AKI is a significant Problem: A deeper dive Acute Kidney Injury (AKI) is a sudden loss of kidney function that is often linked to severe illness and driven by excessive inflammation often making kidneys unable to effectively filter waste and excess fluid which is treated with renal replacement thera
Slide 21: AKI in the US – A Significant Unmet Medical Need
AKI in the US – A Significant Unmet Medical Need Cost Burden4 $21,250 (Current Standard of Care) Total Hospital Admissions1 34,426,650 All-Cause AKI Incidence2 Treatment Price 6,885,330 $10,625 (Target Price = 50% Cost Savings) AKI Stage 2/32 2,341,012 Target Patients3 Annual Market Potential5 468,2
Slide 22: CKD is a significant problem
CKD is a significant problem • AKI patients have an increased chance of developing Chronic Kidney Disease (CKD) as a direct result of the damage inflicted by AKI 1 • CKD affects 10% of the global population2 • Worsening renal function as a result of increased inflammation can cause serious damage in
Slide 23: Severe Burn and the Hyperinflammatory Cycle
Severe Burn and the Hyperinflammatory Cycle • Severe burn induces a hypermetabolic response characterized by shock and a hyperactive immune response • This hyperinflammation cycle further exacerbates infection, putting patients at greater risk of developing systemic inflammatory response syndrome (S
Slide 24: Clinical and Preclinical Data
Clinical and Preclinical Data Demonstration of The Potential of Gemini in Target Indications 24
Slide 25: Gemini Corrected Hyperinflammation and Restored Immunocompetence in Patients with CKD in PRIME Clinical Study
Gemini Corrected Hyperinflammation and Restored Immunocompetence in Patients with CKD in PRIME Clinical Study Gemini reduced background cytokine levels relative to placebo1 • Stage 3 or 4 CKD patient peripheral blood mononuclear cells (PBMCs) were collected prior to and 2, 4, and 24 hours post dose
Slide 26: Gemini significantly reduced fibrotic scarring in a rat model of AKI and CKD
Gemini significantly reduced fibrotic scarring in a rat model of AKI and CKD Gemini significantly reduced new collagen deposition1 • The unilateral urinary obstruction (UUO) model is used for studying AKI and CKD • Daily dosing with Gemini significantly reduced renal fibrosis, or scarring, relative
Slide 27: Gemini significantly improved organ function in a rat model of AKI
Gemini significantly improved organ function in a rat model of AKI Pre-treatment with Gemini significantly reduced serum creatinine (A) 1 and neutrophilic infiltration (B) 2 A. B. • The ischemic reperfusion injury (IRI) model is used to study AKI • Dosing Gemini 24 and/or 48 hours prior to IR: o Sig
Slide 28: Cytokine and Cellular Upregulation in Humans Agree with Animal Models
Cytokine and Cellular Upregulation in Humans Agree with Animal Models Cytokine Upregulation in Humans (Phase 1 study data in healthy volunteers) IL1-RA IL-10 NGAL Neutrophil Cytokine Upregulation in Healthy Animals IL1-RA IL-10 NGAL Neutrophil 28
Revelation Biosciences — Investor Presentation (February 2026) on 6ix